Rome is the only Italian station "Bug Bus"This is a European tour pfizer organized to raise awareness of the problem of antibiotic resistance, that is, the ability of the bacteria to mutate and become resistant to antibiotics. The issue of which the company is strongly committed to the global level and which has various causes, primarily the growing and inadequate use of antibiotics not only in health care, but also in the veterinary world and in the environment. Resistance to antibiotics is now an emergency in the world that, according to VHO, causes over 700,000 deaths annually with a rising trend, which in 2050 could cause at least 10 million deaths a year, which is alarming statistics compared to 8.2 million deaths from cancer planned for the same year.
Every year in Italy, 7% to 10% of hospitalized patients experience a multiresistant bacterial infection and thousands of deaths; In our country, the antibiotic resistance is actually one of the highest, well above the European average. In Europe, there are 4 million infections of antibiotic-resistant calls every year that cause 37,000 deaths and cost about 1.5 billion euros a year.
Bug Bus, an initiative sponsored by Region Lazio and implemented on the occasion of the World Week on Antibiotic Resistance (November 12 and 18), promoted by the World Health Organization, is stopping today at Piazza Bucharest to inform and sensitize the public with a guided bypass allows you to explore the theme in a fun way through "Battle the Bacteria": a game-quiz with questions that test the public's knowledge of bacteria and the phenomenon of resistance to antibiotics. "Battle the Bacteria" also has a charity goal, as Pfizer will donate 1 Euro for each person to play the game, Fondazione Dottor Sorriso ONLUS, who has been dealing with clown therapy since 1995 with a basic mission of facilitating the stay of a smaller patient in the hospital. The team of clown doctors consists of experts specially trained to visit hospitals and rehabilitation institutions every week throughout Italy to give a smile to the children in the hospital.
"Pfizer is leading us to contribute to the improvement of global public health by encouraging patients in the fight against infection," said Imanol Echevarria, Pfizer Anti-Infective's leading therapy company, "We will continue to work closely with you. Contact governments, legislators and health organizations develop solutions and share resources to reduce the global impact of antibiotic resistance. "
"In an emergency situation for multi-resistant infections, both globally and in Italy, Pfizer increasingly confirms its role as a reference partner for the scientific community and health workers in the fight against bacterial and fungal infections." – added Barbara Capaccetti, medical director of Pfizer in Italy – "Education, scientific update and innovation of processes, tools and organizational models are just some of the areas in which the company is actively present together with all stakeholders involved in the prevention and treatment of disease in the community and hospitals, promoting a culture of health that, on the basis of a common and sustainable way, affects both the better use of existing resources and the development of new ones. "
BEHAVIOR MAINTAINED CONTRAST OF ANTIBIOTIC RESISTANCE
In addition to the efforts the scientific community can make in the field of infections, there are behaviors that anyone can adopt every day to prevent development and limit the spread of resistance to antibiotics. First of all, do not take medication, especially antibiotics, without real need. For example, antibiotics – which affect bacteria – are not effective in treating a common flu, which is in most cases caused by viruses. If the antibiotic is prescribed, it is necessary to take it according to your doctor's instructions. It is important to complete the prescribed treatment, do not miss out on any dose, and you do not take medication prescribed for other people or for other indications. Prevent infections by performing the vaccinations provided by the vaccination schedule.
Pfizer is one of the world's leaders in the field of anti-infective drugs and is engaged in various areas for resistance to resistance-resistance (AMR) through:
• Training and education of medical experts in the field of antibiotic therapy
• Innovative monitoring tools such as the Antimicrobial Testing Leadership and Surveillance (ATLAS) that provides clinicians and the global scientific community with information on sensitive profiles of various bacterial strains isolated from more than 70 countries. In January 2018, the first independent report on the activities of pharmaceutical companies Antimicrobial Resistance Benchmark 2018, published by the non-profit organization Access to Medicines Foundation, underlined that the ATLAS program "exceeds all anti-microbial control programs is fully accessible to the entire scientific community "
• A global line of activities that facilitates access to drugs and vaccines and provides accessibility
• Wide and diverse portfolio of anti-infective products (vaccines and antibiotics) to prevent and treat serious infections
• Use of responsible production processes that minimize the impact on human health and the environment
ANTIBIOTIC RESISTANCE (AMR)
The World Health Organization today considers antibiotic resistance (AMR) as one of the most important threats to global public health; resistance to antibiotics can affect anyone at any age and in any country, threatening our ability to treat serious infections and safely managing standard medical procedures. Bacteria become resistant to many existing antibiotic treatments, causing many healthcare infections, which are associated with increased patient mortality and social costs.
PFIZER IN ANTI-INFECTIVE AUTHORITY
Today, Pfizer is a global leader in the portfolio of vaccines and anti-infective drugs available to patients around the world. Since her pioneering work on penicillin in the 1940s, she has been actively engaged in the research and development of innovative medicines and the creation of educational norms and programs for meeting the needs of patients and doctors in this field.
Pfizer recognizes a serious threat to public health due to antibiotic resistance and has taken significant steps to address the problem. At the beginning of 2016, he signed a Anti-Microbial Resistance Anti-Microbial Response Campaign, a global call for action, developed and signed by more than 100 companies and 13 industry associations that encourage greater cooperation between industry and government to address the problem of antibiotic resistance.
Following Davos's statement, Pfizer and 12 other industrial partners presented Roadmap Industries to Combat Antimicrobial Resistance, which establishes four fundamental points (production processes and environmental impacts, research and development, HCP education for adequate use;) dedicated to maintenance until 2020.
At the beginning of this year, Pfizer was recognized by the Antimicrobial Resistance Benchmark 2018 report by the non-profit organization Access to Medicines Foundation, one of the best companies in the anti-infective field, recognizing its role of avant-garde monitoring thanks to the ATLAS database, strong dedication in the production field and a solid gas pipeline in the field of vaccine.
PFIZER: WORKED CLOSED FOR MORE HEALTHCARE
Health is fundamental to all of us. Finding sustainable solutions to the most pressing global challenges is a top priority. That is why Pfizer is dedicated to the application of our scientific knowledge and resources to improve health and well-being at every stage of our lives.
We can count on the portfolio of leading products, from medicines to vaccines, to the most famous vitamins of our consumers, as well as on numerous treatments in a wide range of therapeutic areas, as well as on a promising gas pipeline in challenging the most obvious diseases of our time.
As one of the most important biopharmaceutical companies in the world, and in accordance with our social responsibility, we work with health workers, governments and local communities to support and facilitate access to safe and effective care for the people they need and for health services around the world.
For more than 150 years, Pfizer is working to make a difference. © REZERVIRANA REPRODUKCIJA